Automate Your Wheel Strategy on ATRC
With Tiblio's Option Bot, you can configure your own wheel strategy including ATRC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATRC
- Rev/Share 10.1297
- Book/Share 9.5925
- PB 3.5434
- Debt/Equity 0.1703
- CurrentRatio 4.1078
- ROIC -0.0676
- MktCap 1682671551.0
- FreeCF/Share 0.004
- PFCF 8950.3806
- PE -42.1964
- Debt/Assets 0.1308
- DivYield 0
- ROE -0.0829
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ATRC | JP Morgan | -- | Overweight | -- | $40 | Dec. 17, 2024 |
News
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Published: May 23, 2025 by: Business Wire
Sentiment: Neutral
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference. AtriCure's management is scheduled to host a fireside chat on Monday, June 9, 2025, at 4:00 p.m. Eastern Standard Time. Interested parties may acc.
Read More
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Neutral
AtriCure, Inc. (NASDAQ:ATRC ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Matthew O'Brien - Piper Sandler Companies John McAulay - Stifel Financial Corp. Lily Lozada - JPMorgan Chase & Co. Marie Thibault - BTIG, LLC Danny Stauder - Citizens JMP Securities, LLC Mike Matson - Needham & Company, LLC Danielle Antalffy - UBS Group AG Suraj Kalia - Oppenheimer & Co. Inc. Operator Good afternoon, …
Read More
AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
AtriCure, Inc. (NASDAQ:ATRC ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan William Plovanic - Canaccord Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Rick Wise - Stifel Mike Matson - Needham & Company Danny Stauder - Citizens JMP Danielle Antalffy - UBS Suraj Kalia - Oppenheimer Matthew O'Brien - Piper Sandler Operator Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. …
Read More
About AtriCure, Inc. (ATRC)
- IPO Date 2005-08-05
- Website https://www.atricure.com
- Industry Medical - Instruments & Supplies
- CEO Mr. Michael H. Carrel
- Employees 1300